Age-modified cells and methods for making age-modified cells

a technology of age-modified cells and cells, applied in the field of age-modified cells and methods for making age-modified cells, can solve the problems of limited symptom relief, limited treatment options, and increasing burden on society of neurodegenerative disorders such as parkinson's disease or alzheimer's disease, and achieve the effect of accelerating aging and/or maturation of cells

Inactive Publication Date: 2018-08-16
MEMORIAL SLOAN KETTERING CANCER CENT
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes how a protein called progerin-like protein can be used to speed up the aging and maturation of cells. This allows researchers to create cells that model late-onset diseases, which are often difficult to study properly. The technique could be useful for studying certain cancers and other degenerative conditions.

Problems solved by technology

For example, neurodegenerative disorders such as Parkinson's disease (PD) or Alzheimer's disease (AD) are becoming a growing burden to society.
Only symptomatic relief is available, limited in terms of both the symptoms treated and the duration of its effectiveness, highlighting the need for novel preventive and therapeutic approaches.
Late-onset neurodegenerative disorders such as Parkinson's disease (PD) are becoming a growing burden to society due to the gradual increase in life expectancy.
A problem in addressing the global aspects of aging and rejuvenation during cell reprogramming and differentiation is the identification of markers that reliably predict the chronological age of the somatic cell donor and the corresponding cellular age of iPSC derivatives.
The ability to measure and manipulate age in cells differentiated from iPSCs represents a fundamental challenge in pluripotent stem cell research that remains unresolved to date.
There has been considerable progress in directing cell fate into the various derivatives of all three germ layers; however, there has been no technology to switch the age of a given cell type on demand from embryonic to neonatal, adult or aged status.
This remains a major impediment in the field as illustrated by the persistent failure to generate hiPSC-derived adult-like hematopoietic stem cells, fully functional cardiomyocytes, or mature pancreatic islets and the general inability to derive aged cell types that are age-appropriate and / or stage-appropriate for modeling late-onset diseases.
iPSC models of late-onset disorders such as PD do not adequately reflect the severe degenerative pathology of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Age-modified cells and methods for making age-modified cells
  • Age-modified cells and methods for making age-modified cells
  • Age-modified cells and methods for making age-modified cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

Sendai Vector System Reprogramming

[0179]This example describes an integration-free reprogramming technique via a Sendai vector system. Fusaki et al., Proc Japan Acad Ser B:348-362 (2009). This method with such modifications as are described below was used to reprogram somatic cells into iPSC.

[0180]It is believed that this method eliminates concerns about insertional mutagenesis induced by integration of the reprogramming vectors contributing to phenotype. For example, this method has generated an integration-free HGPS iPSC cell line (FIG. 18).

example 2

Progerin Transduction into iPSC-Derived Somatic Cell Culture

[0181]This example illustrates methods for the introduction of a progerin gene into iPSC-derived somatic cultures using a synthetic mRNA approach (Warren et al., Cell Stem Cell 7:618-630 (2010)) or various vectors. Unlike stable transfection techniques, the addition of mRNAs allows for easy manipulation of the duration of gene expression. This advantage is utilized discontinue progerin expression and to monitor the effects following protein turnover (See, FIG. 19). This protocol can be used to introduce any other progerin-like protein into a cell, whether iPSC, primary stem cell, embryonic stem cell or primary or cultured somatic cell not derived from an iPSC.

[0182]The following is a protocol for progerin overexpression using modified-RNA in differentiating or differentiated iPSC-derived cells:[0183]1. Prepare progerin-modified-RNA (methods of synthesis are described in Example 9) and deliver to iPSC-derived somatic cells u...

example 3

Directed Differentiation of Neuronal Cell Types

[0191]This example describes one method of directed differentiation techniques to generate specific neural cell types. Nearly pure populations of CNS lineages, such as midbrain dopamine (mDA) neurons, are used in the methods described herein. The protocol of Kriks et al, Nature 2011, infra, can be used (among other methods).

[0192]Briefly, a modified version of the dual-SMAD inhibition protocol was used to direct cells towards floor plate-based mDA neurons as described previously (Kriks et al., Nature 480:547-551 (2011) and schematized in FIG. 8. iPSC-derived mDA neurons were replated on day 30 of differentiation at 260,000 cells per cm2 on dishes pre-coated with polyornithine (PO; 15 μg / ml) / Laminin (1 μg / ml) / Fibronectin (2 μg / ml) in Neurobasal / B27 / L-glutamine-containing medium (NB / B27; Life Technologies) supplemented with 10 μM Y-27632 (until day 32) and with BDNF (brain-derived neurotrophic factor, 20 ng / ml; R&D), ascorbic acid (AA; 0....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided are age-modified cells and method for making age modified cells using progerin or a progerin-like protein. The aging and / or maturation process can be accelerated and controlled for young and / or immature cells, such as a somatic cell, a stem cell, a stem cell-derived somatic cell, including an induced pluripotent stem cell-derived cell, by contacting with progerin or a progerin-like protein. Methods described by the present disclosure can produce age-appropriate cells from a somatic cell or a stem cell, such as an old cell and / or a mature cell. Such age-modified cells constitute model systems for the study of late-onset diseases and / or disorders.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Divisional of U.S. patent application Ser. No. 14 / 884,503, filed Oct. 15, 2015, which is a Continuation of International Patent Application No. PCT / US2014 / 034435, filed Apr. 16, 2014, and claims priority to U.S. Provisional Application No. 61 / 812,464, filed on Apr. 16, 2013, and U.S. Provisional Application No. 61 / 907,262, filed on Nov. 21, 2013, the contents of each of which are hereby incorporated by reference in their entirety herein, and to each of which priority is claimed.GRANT INFORMATION[0002]The work described in this disclosure was funded in part by an NSF fellowship, DGE-1144470. The U.S. government may have certain rights in this disclosure.SEQUENCE LISTING[0003]The specification further incorporates by reference the Sequence Listing submitted herewith via EFS on Apr. 2, 2018. Pursuant to 37 C.F.R. § 1.52(e)(5), the Sequence Listing text file, identified as “072734_0679SEQ.TXT,” is 11,504 bytes and was cr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N5/079G01N33/50C12N5/074
CPCG01N33/5058C12N2503/02C12N5/0618C12N5/0696G01N33/502G01N33/5023C12N2506/1307G01N33/5073C12N2501/40C12N2501/998
Inventor STUDER, LORENZMILLER, JUSTINE D.
Owner MEMORIAL SLOAN KETTERING CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products